DeepMed Research

University of Minnesota Masonic Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases

Not Applicable

Terminated

Conditions: Burkitt's Lymphoma
Chronic Myelogenous Leukemia
Acute Leukemias

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: Total Body Irradiation
Biological: Haploidentical stem cell transplant

First Posted Date: 2014-05-22

Last Posted Date: 2019-12-26

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 2

Registration Number: NCT02145039

Locations: 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL

Phase 1

Completed

Conditions: Diffuse Large B Cell Non-Hodgkin Lymphoma

Interventions: Drug: Rituximab
Drug: INCB7839

First Posted Date: 2014-05-19

Last Posted Date: 2020-02-19

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 30

Registration Number: NCT02141451

Locations: 🇺🇸
University of Minnesota Medical Center, Fairview, Minneapolis, Minnesota, United States

Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Ovarian Cancer
Primary Peritoneal Carcinoma
Fallopian Tube Carcinoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: NK cells
Biological: IL-2
Drug: INCB024360

First Posted Date: 2014-04-21

Last Posted Date: 2017-12-05

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 2

Registration Number: NCT02118285

Locations: 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

Treg Cells for AGVHD in Non-myeloablative UCB Transplant

Phase 2

Withdrawn

Conditions: Hematologic Malignancies

Interventions: Biological: T Regulatory cells
Drug: Fludarabine
Radiation: Total Body Irradiation
Drug: Cyclophosphamide

First Posted Date: 2014-04-21

Last Posted Date: 2017-12-02

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Registration Number: NCT02118311

Locations: 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation

Phase 2

Completed

Conditions: Osteopenia
Osteoporosis

Interventions: Drug: Pamidronate
Drug: Calcium and vitamin D

First Posted Date: 2014-02-28

Last Posted Date: 2024-02-20

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 63

Registration Number: NCT02074631

Locations: 🇺🇸
University of Minnesota Amplatz Children's Hospital, Minneapolis, Minnesota, United States
🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States

Safety of Romiplostim (Nplate®) Following UCBT

Phase 1

Completed

Conditions: Hematologic Malignancies

Interventions: Drug: Romiplostim

First Posted Date: 2014-01-27

Last Posted Date: 2021-06-08

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 21

Registration Number: NCT02046291

Locations: 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

Pilot Study of Multi-Modality Imaging in Patients With Hematologic Malignancies

Not Applicable

Terminated

Conditions: Hematologic Malignancy

Interventions: Radiation: FLT PET/CT
Device: MRI

First Posted Date: 2014-01-23

Last Posted Date: 2017-12-05

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 2

Registration Number: NCT02042924

Locations: 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Not Applicable

Recruiting

Conditions: Acute Myeloid Leukemia (AML)
Acute Lymphocytic Leukemia (ALL)
Myelodysplasia
Chronic Lymphocytic Leukemia
Marginal Zone B-Cell Lymphoma
Follicular Lymphoma
Non-Hodgkin Lymphoma
Multiple Myeloma
Chronic Myelogenous Leukemia
Plasma Cell Leukemia

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: Total Body Irradiation
Drug: Cyclosporine A
Drug: Mycophenylate mofetil
Biological: Umbilical cord blood

First Posted Date: 2013-10-14

Last Posted Date: 2024-11-04

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 200

Registration Number: NCT01962636

Locations: 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT

Phase 1

Completed

Conditions: Acute Myelogenous Leukemia (AML)
Chronic Lymphocytic Leukemia (CLL)
Acute Lymphoblastic Leukemia (ALL)
Myelodysplastic Syndromes (MDS)
Lymphoma
Myeloma
Chronic Myelogenous Leukemia (CML)

Interventions: Biological: ALT-803

First Posted Date: 2013-06-25

Last Posted Date: 2020-08-12

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 33

Registration Number: NCT01885897

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

MIBG for Refractory Neuroblastoma and Pheochromocytoma

Not Applicable

Suspended

Conditions: Metastatic Pheochromocytoma
Relapsed Neuroblastoma

Interventions: Drug: 131 I-Metaiodobenzylguanidine (131I-MIBG)
Drug: Potassium iodide solution
Drug: G-CSF
Procedure: hematopoietic stem cell infusion

First Posted Date: 2013-05-10

Last Posted Date: 2025-02-04

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 100

Registration Number: NCT01850888

Locations: 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy